GHRP-6

Synthetic hexapeptide growth hormone secretagogue and ghrelin mimetic used to probe GH release, appetite regulation and energy balance.

Evidence: Human + Preclinical Function: GH & Appetite Research Class: GHSR agonist (GHRP)

Explore calculators for this peptide

Use the Peptide Research Tools to experiment with reconstitution, mg/kg ranges and simplified half-life curves for GHRP-6. All values are placeholders and must be aligned with your own research protocol.

Open GHRP-6 in calculators →

Research frame & potential applications

GHRP‑6 (Growth Hormone Releasing Peptide‑6) is a ghrelin‑mimetic hexapeptide that activates the growth hormone secretagogue receptor (GHSR1a), triggering pulsatile GH release and robust appetite stimulation. It is widely used in experimental settings to study GH axis physiology, feeding behaviour, metabolic regulation and the interplay between hunger signals and endocrine responses.

Research areas & putative benefits

Experimental contexts where GHRP‑6 is used as a probe or tool compound.

Characterising pulsatile GH release and pituitary responsiveness in healthy and diseased endocrine states.
Studying appetite regulation, hunger signalling and feeding behaviour via ghrelin‑pathway activation.
Exploring metabolic effects of repeated GH secretagogue pulses on body composition, glucose and lipid handling in research models.
Evaluating synergy and pathway interactions when combined with GHRH analogues or other GH‑axis modulators.

Mechanism stack

Core signalling pathways engaged by GHRP‑6 in GH and appetite research.

Primary receptor

GHSR1a agonism

GHRP‑6 binds to the growth hormone secretagogue receptor (GHSR1a) in the pituitary and hypothalamus, mimicking ghrelin’s action and triggering GH release via a pathway distinct from classical GHRH receptors.

GH axis

Pulsatile GH secretion

Activation of GHSR1a induces robust, short‑lived spikes in circulating growth hormone, often enhanced when combined with GHRH analogues, providing a model for studying pulsatile GH physiology.

Appetite

Hypothalamic NPY/AgRP circuit

In the hypothalamus, GHRP‑6 engages GHSR‑expressing neurons, including NPY/AgRP populations, leading to pronounced increases in hunger signalling and food‑seeking behaviour in animal models.

Metabolism

Energy balance & GH/IGF axis

Repeated GH secretagogue pulses allow investigation of how GH‑IGF‑1 signalling interacts with glucose tolerance, lipid metabolism and body composition in various experimental paradigms.

Evidence snapshot

Selected findings from GH, appetite and mechanistic studies on GHRP‑6.

Model / context	Observation	Notes
Human GH secretion tests Endocrine	Intravenous or intranasal GHRP‑6 produces marked, short‑duration increases in circulating GH, comparable to other GHSR agonists and often additive with GHRH.	Commonly used as a pharmacological stimulus to evaluate pituitary GH reserve and hypothalamic–pituitary axis function.
Appetite experiments in animals Feeding behaviour	GHRP‑6 administration rapidly increases food intake and reduces locomotor activity in several species, consistent with a hunger‑promoting, energy‑conserving profile.	Useful for exploring appetite pathways and testing anti‑orexigenic counter‑interventions.
GHRP‑6 vs GHRP‑2 & ghrelin Comparative	Comparative research shows GHRP‑6 has relatively strong appetite stimulation and GH release, with a profile closer to ghrelin than some other secretagogues.	Highlights its value as a tool for dissecting ghrelin‑specific signalling components.
Metabolic & body-composition work Preclinical metabolic	GHRP‑6‑induced GH pulses have been explored for effects on lean mass, adiposity and insulin sensitivity in animal models, with context‑dependent outcomes.	Findings are heterogeneous and heavily protocol‑dependent, emphasising research‑only framing.

Risk frame & unknowns

Considerations when interpreting GHRP‑6 research data.

Important research caveats

Chronic or supraphysiological GH/ghrelin‑pathway activation may impact glucose tolerance, water retention and cardiovascular risk in ways not fully characterised.
Most work focuses on acute responses; long‑term adaptation, desensitisation and receptor down‑regulation are less well mapped.
Appetite stimulation may confound attempts to isolate GH‑specific effects in some models.
Use outside controlled research environments risks significant off‑target metabolic effects and misuse in performance‑enhancement contexts.

This dossier summarizes mechanistic, preclinical and clinical findings on GHRP‑6 for scientific and educational purposes only. It does not provide medical advice, treatment guidance or dosing recommendations.